Phosphogliv, lyophilizate. 500 mg+200 mg 2.5g 5 pcs

Combined remedy.

It has membrane stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the main component of phospholipids) is the main structural element of cell and intracellular membranes and can restore their structure and functions in case of damage, providing a cytoprotective effect.

Normalizes protein and lipid metabolism, prevents loss of enzymes and other active substances by hepatocytes, restores liver function, inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.

Glycyrrhizic acid has anti-inflammatory effects, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis and increasing the activity of natural killer cells.

It has hepatoprotective effect due to antioxidant and membrane stabilizing activity. Glycyrrhizic acid potentiates the effect of endogenous glucocorticosteroids with anti-inflammatory and anti-allergic effect in non-infectious liver lesions.

In skin lesions due to the membrane stabilizing and anti-inflammatory action of the components limits the spread of the process and promotes the regression of the disease.

Pharmacokinetics.

Phosphatidylcholine
Binding primarily to high-density lipoproteins, phosphatidylcholine is delivered, particularly to liver cells. Half-life of the choline component is 66 hours, and of unsaturated fatty acids – 32 hours.
Glycyrrhizic acid
Glycyrrhizic acid, entering the systemic bloodstream, is bound to albumin and transported to the liver. Glycyrrhizic acid is excreted with bile in unchanged form, in residual amount – with urine. On entering the intestine some of it is hydrolyzed under the action of β-glucuronidase of the intestinal microflora into β-glycyrrhetic acid which is reabsorbed causing enterohepatic circulation.
An experimental data, the inclusion of glycyrrhizic acid in phospholipid nanoparticles improves its pharmacokinetic and pharmacodynamic properties, prolongs the circulation in the blood and increases the entry into the liver.

In addition, the inclusion of glycyrrhizic acid in phospholipid nanoparticles contributes to improving its pharmacokinetic and pharmacodynamic properties.

Indications

Active ingredient

Composition

1 vial contains:

Active ingredients:

Phospholipids (Lipoid C 100) – 0.50 g

Trisodium salt of glycyrrhizic acid (sodium glycyrrhizinate) – 0.20 g

Ancillary substance:

Maltose – 1.80 g

How to take, the dosage

Interaction

Special Instructions

The contents of the bottle must not be mixed with other solutions. Only water for injection should be used for dissolution. Do not use physiological sodium chloride solution or glucose solution to dilute the drug. It is administered only by intravenous stream.

Influence on the ability to drive vehicles, mechanisms

Data on the adverse effect of Fosfogliv® on driving and engaging in potentially hazardous activities requiring increased concentration and quick psychomotor reactions are not available.

Contraindications

Hypersensitivity to the ingredients of the drug, pregnancy, lactation, children under 12 years.

Side effects

Overdose

Pregnancy use